Medical device company Aethlon Medical Inc (Nasdaq:AEMD) reported on Tuesday the receipt of the European Patent entitled 'Extracorporeal Removal of Microvesicular Particles' for the use of the Hemopurifier technology in the treatment of cancer.

The patent, which has been assigned the No. 1,993,600 (the 600 Patent), embodies the company's Hemopurifier technology designed for the depletion of immune suppressive and potentially cancer-promoting, exosomes from the circulatory system.

According to the company, the Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections. In preclinical studies in cancer, the Hemopurifier depletes the presence of circulating tumour-derived exosomes that are believed to promote immune suppression. These tumour derived exosomes may inhibit the benefit of leading cancer therapies.

Additionally, the company has demonstrated the ability of laboratory versions of the Hemopurifier to capture exosomes underlying several forms of cancer, including breast, ovarian and melanoma, in laboratory experiments.

In November 2018, the company announced US FDA Breakthrough Device designation to support the advancement of the Hemopurifier for the treatment of cancer. In October 2019, the US FDA approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Hemopurifier in patients with advanced head and neck cancer.